FDA Brief

Warning letters Food

FDA warning letter to

JLM Nutritionals, Inc. dba JLM Nutrition—Super Naturals Health

High riskIssued May 26, 2021Posted Jun 29, 2021Office of Human and Animal Food Operations- West Division 5

FDA says JLM Nutritionals marketed five Super Naturals supplements as unapproved drugs with disease claims on websites, Amazon, and Facebook.

What happened

In May 2021, FDA reviewed websites supernaturalshealth.com and ibsformula.com, related Amazon pages, and Facebook pages. FDA found claims that Super Naturals IBSolution, Premium Probiotic, Sleep Solution, Joint Solution, and Ultra Omega Fish Oil treat or prevent diseases such as IBS, cancer, heart disease, depression, arthritis, and diabetes. FDA concluded the products are unapproved new drugs and misbranded because they lack adequate directions for use.

What FDA found

  1. FDA says the websites, Amazon pages, and Facebook posts show the products are intended to treat or prevent diseases, which makes them drugs.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. FDA says the products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and lack FDA approval.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. FDA says the products are misbranded because they do not have adequate directions for a layperson to use them safely for the claimed disease uses.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA says introducing or delivering these misbranded drugs into interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter about steps taken to address the violations, including steps to prevent recurrence and related documentation. If corrective actions cannot be completed in that time, the company must state the reason and the time within which it will do so.

Who should pay attention

  • dietary supplement brands that make disease-treatment claims
  • online retailers and marketplaces hosting supplement listings
  • marketing teams running health-claim content for supplement companies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk